CorMedix to acquire substantially all assets of Heron Therapeutics for $145M cash
FROM THE WIRE · GLOBENEWSWIRE.COM
Adds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralPortfolio deal with a share component and a $75M financing, relevant for CorMedix.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Heron receives $145M in cash plus 14,583,333 CorMedix shares.
- 02Earn-out of up to $55M tied to 2028 ZYNRELEF net sales.
- 03Expected near-term operating cost synergies of $45-60M.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets